Ponatinib is a third-generation TKI that can obtain favorable responses in the majority of patients, with chronic-phase CML [66], whereas asciminib eschews binding to the ATP binding site of BCR-ABL1 (where the other TKIs bind) for the myristoyl site in order to lock the BCR-ABL1 protein in an inactive conformation [67]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.